Cynata Therapeutics Limited (AU:CYP) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cynata Therapeutics Limited has announced results from a study showing their Cymerus™ MSC therapy can significantly reverse pulmonary fibrosis and lung stiffness, offering hope for a novel treatment option for this fatal lung disease. This therapy, derived from induced pluripotent stem cells, demonstrated potent anti-inflammatory effects and the restoration of lung compliance in a preclinical model. The study, which aligns with Cynata’s focus on regenerative medicine, was published in the journal Biomedicine & Pharmacotherapy.
For further insights into AU:CYP stock, check out TipRanks’ Stock Analysis page.